Anzeige
Mehr »
Freitag, 24.10.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40YLC | ISIN: US48576U2050 | Ticker-Symbol: 25K0
Tradegate
23.10.25 | 19:25
5,450 Euro
+2,83 % +0,150
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
KARYOPHARM THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
KARYOPHARM THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,2505,45009:03
5,2505,45009:00

Aktuelle News zur KARYOPHARM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.10.Karyopharm Therapeutics stock rating upgraded to Buy by H.C. Wainwright3
KARYOPHARM Aktie jetzt für 0€ handeln
09.10.Karyopharm stock price target lowered to $12 at Piper Sandler on restructuring2
08.10.Karyopharm: Leerink Partners reduziert Kursziel auf 6 US-Dollar4
08.10.Karyopharm Therapeutics stock price target lowered to $6 at Leerink Partners3
08.10.Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 20262
08.10.Karyopharm Therapeutics Stock Falls 13% After Announcing $100 Mln Financing Deal2
08.10.Karyopharm rises on securing $100M in financing to extend cash runway into Q2 20262
08.10.Karyopharm secures $100 million in financing to extend cash runway2
08.10.Karyopharm Therapeutics Inc. - 8-K, Current Report9
08.10.Karyopharm Therapeutics Inc.: Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis81- Transactions Provide Karyopharm with $100 Million of Financial Flexibility and Additional Capital - - Preliminary Total Revenue and U.S. XPOVIO® (selinexor)...
► Artikel lesen
01.10.Karyopharm Therapeutics Inc.: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)44NEWTON, Mass., Oct. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies...
► Artikel lesen
11.09.Karyopharm Therapeutics Inc. - 8-K, Current Report2
10.09.Karyopharm completes enrollment in phase 3 myelofibrosis trial3
10.09.Karyopharm Therapeutics Inc.: Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis466- Top-Line Results Anticipated in March 2026 - NEWTON, Mass., Sept. 10, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage...
► Artikel lesen
02.09.Karyopharm Therapeutics Inc.: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)74NEWTON, Mass., Sept. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies...
► Artikel lesen
11.08.Karyopharm outlines $1B peak U.S. revenue opportunity in myelofibrosis with pivotal Phase III data expected by March 202617
11.08.Karyopharm Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans1
11.08.Karyopharm Therapeutics GAAP EPS of -$4.32 misses by $0.29, revenue of $37.93M in-line4
11.08.Karyopharm Therapeutics Inc. - 10-Q, Quarterly Report1
11.08.Karyopharm Therapeutics Inc. - 8-K, Current Report1
Weiter >>
55 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2